Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jiří Drahota"'
Autor:
Dominika Stastna, Jiri Drahota, Michal Lauer, Aneta Mazouchova, Ingrid Menkyova, Jana Adamkova, Radek Ampapa, Michal Dufek, Marketa Grunermelova, Pavel Hradilek, Eva Kubala Havrdova, Jan Mares, Alena Martinkova, Zbysek Pavelek, Marek Peterka, Eva Recmanova, Petra Rockova, Ivana Stetkarova, Pavel Stourac, Marta Vachova, Dana Horakova
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 262-270 (2024)
Aims. Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual da
Externí odkaz:
https://doaj.org/article/031942c91d96488a818590beaafcebd7
Autor:
Dana Horáková, Marta Vachová, Aleš Tvaroh, Jiří Drahota, Aneta Mazouchová, Jan Mareš, Ivana Woznicová, Denisa Zimová, Jana Libertínová, Alena Martinková, Eva Recmanová, Markéta Grunermelová, Martin Vališ, Jana Adámková, Radek Ampapa, Yvonne Benešová, Michal Dufek, Marek Peterka, Eva Kubala Havrdová
Publikováno v:
Česká a slovenská neurologie a neurochirurgie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83048c331b45f1e0427846f59411c7c0
https://doi.org/10.48095/cccsnn2021555
https://doi.org/10.48095/cccsnn2021555
Autor:
Pavel Potuznik, Jiri Drahota, Dana Horakova, Marek Peterka, Aneta Mazouchova, David Matyas, Zbysek Pavelek, Marta Vachova, Eva Recmanova, Ivana Stetkarova, Jana Libertinova, Jan Mares, Pavel Stourac, Marketa Grunermelova, Alena Martinkova, Jana Adamkova, Pavel Hradilek, Radek Ampapa, Michal Dufek, Eva Kubala Havrdova, Dominika Stastna
Publikováno v:
Journal of Central Nervous System Disease, Vol 16 (2024)
Background Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). Objectives Provide experience with cladribine therapy in a real-world setting. Methods This
Externí odkaz:
https://doaj.org/article/184f4c6999bb4bada8b072f3e0cb99d2
Autor:
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke Van Der Walt, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Dana Horáková, Jirí Drahota, Fabio Pellegrini, Robert Hyde, Pierre Duquette, Jeannette Lechner-Scott, Seyed Aidin Sajedi, Patrice Lalive, Vahid Shaygannejad, Serkan Ozakbas, Sara Eichau, Raed Alroughani, Murat Terzi, Marc Girard, Tomas Kalincik, Francois Grand'Maison, Olga Skibina, Samia J. Khoury, Bassem Yamout, Maria Jose Sa, Oliver Gerlach, Yolanda Blanco, Rana Karabudak, Celia Oreja-Guevara, Ayse Altintas, Stella Hughes, Pamela McCombe, Radek Ampapa, Koen de Gans, Chris McGuigan, Aysun Soysal, Julie Prevost, Nevin John, Jihad Inshasi, Leszek Stawiarz, Ali Manouchehrinia, Lars Forsberg, Finn Sellebjerg, Anna Glaser, Luigi Pontieri, Hanna Joensen, Peter Vestergaard Rasmussen, Tobias Sejbaek, Mai Bang Poulsen, Jeppe Romme Christensen, Matthias Kant, Morten Stilund, Henrik Mathiesen, Jan Hillert, The Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundTreatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors of treatme
Externí odkaz:
https://doaj.org/article/3d52ca1fdc794fa48cba7a9cc328885d
Autor:
Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van Der Walt, Vladimir Bezlyak, Carol Lines, Rod Middleton
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising
Externí odkaz:
https://doaj.org/article/94019eea78bf46cdb31bf422481b6086